A Phase II Study of AT 101 [(-) enantiomer of gossypol] to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer.

Trial Profile

A Phase II Study of AT 101 [(-) enantiomer of gossypol] to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2012

At a glance

  • Drugs AT 101 (Primary) ; Bicalutamide; Gonadotropin releasing hormone stimulants
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Actual end date ( May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top